In addition, Celldex would have two active preclinical programs. Under the terms of the agreement, Celldex will acquire Kolltan in a stock-for-stock transaction, in which the upfront payment represents an equity value of …
The stock currently has Price to Sales (P/S) value of 71.46 where Price to Book (P/B) value stands at 1.73.CLDX is currently showing ROA (Return on Assets) value of -38.3% where ROE (Return on Equity) is -43.4%. Return …
HAMPTON, N.J., Dec. 4, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the pricing of an underwritten public offering of 7,000,000 shares of its common stock, offered at a …
Or maybe it's the decent cash position that Celldex is in, with $203.2 million in the bank after using $24 million for operating activities during the third quarter. The acquisition of Kolltan is an all-stock deal, so it won't hurt …
Celldex Therapeutics Inc. climbed nearly 13 percent after Leerink Swann boosted its price target to $45 from $28, StreetInsider.com reported, adding that the firm is “largely bullish” on CDX-1127, an experimental drug to treat …
Both methods assume that all dividends are reinvested and that no taxes were collected. Both methods also account for stock splits and stock dividends. The specific process used for each is outlined below: The prices …
Earlier in the lifecycle of Rintega, trials were widely regarded as successful and even led to huge gains in Celldex stock. In this pivotal third stage of clinical trials, however, results took a turn for the worst. An interim analysis …
Celldex Therapeutics was once a high-flying stock. But that was before the company's lead candidate, Rintega, flopped in a late-stage study for treating a type of brain tumor. Over the past 12 months, Celldex's shares …
Following the announcement, the company stock plunged. At present, Celldex stock is down 57.63% at $3.47 as of 7:31 AM EST in pre-market hours.
Celldex Therapeutics Inc. (CLDX) traded on unusually high volume on Feb. 02, as the stock gained 4.35% to close at $3.36. On the day, Celldex Therapeutics Inc. saw 4.13 million shares trade hands on 10,469 trades. …